Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase II Trial of Radiotherapy With Concurrent Cisplatin +/- Concurrent Cetuximab for HPV-Positive Oropharyngeal Squamous Cell Carcinoma (OPSCC) in KRAS-Variant Patients

NCT04106362 is registered in ClinicalTrials.gov with Jonsson Comprehensive Cancer Center as lead sponsor.

NCT NCT04106362
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04106362 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase II Trial of Radiotherapy With Concurrent Cisplatin +/- Concurrent Cetuximab for HPV-Positive Oropharyngeal Squamous Cell Carcinoma (OPSCC) in KRAS-Variant Patients
Lead sponsor
Jonsson Comprehensive Cancer Center
Phase
Phase 2
Overall status
Terminated
Start date
January 14, 2020
Completion date
May 23, 2023
Enrollment
1 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

clinical stage iii hpv-mediated (p16-positive) oropharyngeal carcinoma ajcc v8, clinical stage iv hpv-mediated (p16-positive) oropharyngeal carcinoma ajcc v8, kras protein variant, pathologic stage iii hpv-mediated (p16-positive) oropharyngeal carcinoma ajcc v8, pathologic stage iv hpv-mediated (p16-positive) oropharyngeal carcinoma ajcc v8